Vaccination and immunization against travel-related diseases in immunocompromised hosts

Expert Review of Vaccines

Volumn 7, Issue 5, 2008, Pages 663-672

  Kotton, Camille Nelson ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Immunocompromised; Solid organ transplant; stem cell transplant; Travel medicine; Vaccine

Indexed keywords

BCG VACCINE; CHICKENPOX VACCINE; DIPHTHERIA VACCINE; GAMMA INTERFERON; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN; INACTIVATED VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RABIES IMMUNOGLOBULIN; RABIES VACCINE; RECOMBINANT HEPATITIS B VACCINE; RITUXIMAB; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TYPHOID VACCINE; UNINDEXED DRUG; VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG CONTRAINDICATION; GASTROINTESTINAL DISEASE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; INFECTION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; TRAVEL; VACCINATION;

ADULT; HIV SEROPOSITIVITY; HUMANS; IMMUNIZATION; IMMUNOCOMPROMISED HOST; NEOPLASMS; OPPORTUNISTIC INFECTIONS; TRAVEL; VACCINATION;

EID: 45949100102     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.5.663     Document Type: Review

References (72)

1. Boggild AK, Sano M, Humar A, Salit I, Gilman M, Kain KC. Travel patterns and risk behavior in solid organ transplant recipients. J. Travel Med. 11(1), 37-43 (2004). •• The only study to date regarding solid-organ transplant recipients and their behavior toward travel-related issues.
2. No authors listed. Advising travelers with specific needs: the immunocompromised traveler. In: Health Information for International Travel 2007-2008: the Yellow Book. Centers for Disease Control, Department of Health and Human Services, Atlanta, GA, USA (2008). •• Contains detailed comments on immunocompromised travelers, with specific situations addressed.
3. Committee to Advise on Tropical Medicine and Travel (CATMAT). The immunocompromised traveller. An Advisory Committee Statement (ACS). Can. Commun. Dis. Rep. 33(ACS-4), 1-24 (2007).
4. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin. Arthritis Rheum. 33(4), 283-288 (2004).
5. Fishman JA. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357(25), 2601-2614 (2007). • State-of-the-art overview on infections in solid-organ transplant recipients.
6. van der Velden AM, Claessen AM, van Velzen-Blad H et al. Vaccination responses and lymphocyte subsets after autologous stem cell transplantation. Vaccine 25(51), 8512-8517 (2007).
7. Magnani G, Falchetti E, Pollini G et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J. Heart Lung Transplant. 24(5), 588-592 (2005).
8. Nevens F, Zuckerman JN, Burroughs AK et al. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. Liver Transpl. 12(10), 1489-1495 (2006).
9. Rosenau J, Hooman N, Rifai K et al. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl. Int. 19(10), 828-833 (2006).
10. Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298(18), 2155-2163 (2007).
11. Henning KJ, White MH, Sepkowitz KA, Armstrong D. A national survey of immunization practices following allogeneic bone marrow transplantation. JAMA 277(14), 1148-1151 (1997).
12. Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am. J. Transplant. 8(1), 9-14 (2008). • One of the more recent and comprehensive publications on immunizations in solid-organ transplant recipients.
13. Guidelines for vaccination of solid organ transplant candidates and recipients. Am. J. Transplant. 4(Suppl. 10), 160-163 (2004).
14. Ballout A, Goffin E, Yombi JC, Vandercam B. Vaccinations for adult solid organ transplant recipient: current recommendations. Transplant. Proc. 37(6), 2826-2827 (2005).
15. Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin. Microbiol. Rev. 16(3), 357-364 (2003).
16. Kotton CN, Ryan ET, Fishman JA. Prevention of infection in adult travelers after solid organ transplantation. Am. J. Transplant. 5(1), 8-14 (2005).
17. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 33(2), 139-144 (2001). •• Provides specific and helpful guidelines on the use of vaccines after hematopoietic stem cell transplant (HSCT), compiled by North American sources.
18. Ljungman P, Engelhard D, de la Camara R et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 35(8), 737-746 (2005). •• Provides specific and helpful guidelines on the use of vaccines after HSCT, compiled by European sources.
19. Machado CM. Reimmunization after hematopoietic stem cell transplantation. Expert Rev. Vaccines 4(2), 219-228 (2005).
20. Leung AY, Chow HC, Kwok JS et al. Safety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantation. Bone Marrow Transplant. 39(11), 661-665 (2007).
21. Storek J, Viganego F, Dawson MA et al. Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. Blood 101(8), 3319-3324 (2003).
22. Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients - three year follow-up of a randomized trial. Am. J. Transplant. 7(3), 633-638 (2007).
23. Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin. Infect. Dis. 33(Suppl. 1), S15-S21 (2001).
24. Molrine DC, Hibberd PL. Vaccines for transplant recipients. Infect. Dis. Clin. North Am. 15(1), 273-305, xii (2001).
25. Health Information for International Travel 2007-2008: the Yellow Book. Centers for Disease Control, Department of Health and Human Services, Atlanta, GA, USA (2007). •• Outstanding resource for travel-medicine issues. Available free on the internet.
26. Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J. Pediatr. 123(1), 87-89 (1993).
27. Hayney MS, Welter DL, Reynolds AM, Francois M, Love RB. High-dose hepatitis B vaccine in patients waiting for lung transplantation. Pharmacotherapy 23(5), 555-560 (2003).
28. Bienzle U, Gunther M, Neuhaus R et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 38(4), 811-819 (2003).
29. Choy BY, Peiris JS, Chan TM, Lo SK, Lui SL, Lai KN. Immunogenicity of intradermal hepatitis B vaccination in renal transplant recipients. Am. J. Transplant. 2(10), 965-969 (2002).
30. Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am. J. Med. 118(Suppl. 10A), S75-S83 (2005).
31. Jaffe D, Papadopoulos EB, Young JW et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood 108(7), 2470-2475 (2006).
32. Ljungman P, Wang FZ, Nilsson C, Solheim V, Linde A. Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study. Support Care Cancer 11(11), 739-741 (2003).
33. Hata A, Asanuma H, Rinki M et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N. Engl. J. Med. 347(1), 26-34 (2002).
34. Ryan ET, Kain KC. Health advice and immunizations for travelers. N. Engl. J. Med. 342(23), 1716-1725 (2000).
35. Mutsch M, Spicher VM, Gut C, Steffen R. Hepatitis A virus infections in travelers, 1988-2004. Clin. Infect. Dis. 42(4), 490-497 (2006).
36. Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 72(2), 272-276 (2001).
37. Dumot JA, Barnes DS, Younossi Z et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am. J. Gastroenterol. 94(6), 1601-1604 (1999).
38. Stark K, Gunther M, Neuhaus R et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J. Infect. Dis. 180(6), 2014-2017 (1999).
39. Gunther M, Stark K, Neuhaus R, Reinke P, Schroder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 71(3), 477-479 (2001).
40. Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 25(5), 927-931 (2007).
41. Overton ET, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J. Viral Hepat. 14(3), 189-193 (2007).
42. Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV-positive patients. J. Viral Hepat. 13(2), 81-86 (2006).
43. Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS 19(15), 1702-1704 (2005).
44. Wallace MR, Brandt CJ, Earhart KC et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin. Infect. Dis. 39(8), 1207-1213 (2004).
45. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi). Vaccine 17(23-24), 2941-2945 (1999).
46. Begier EM, Burwen DR, Haber P, Ball R. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. Clin. Infect. Dis. 38(6), 771-779 (2004).
47. Ljungman P, Aschan J, Gustafsson B, Lewensohn-Fuchs I, Winiarski J, Ringden O. Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients. Bone Marrow Transplant. 34(12), 1067-1069 (2004).
48. Parkkali T, Kayhty H, Lehtonen H et al. Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients. Bone Marrow Transplant. 27(1), 79-84 (2001).
49. Patel SR, Ortin M, Cohen BJ et al. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin. Infect. Dis. 44(5), 625-634 (2007).
50. Yu JW, Borkowski A, Danzig L, Reiter S, Kavan P, Mazer BD. Immune response to conjugated meningococcal C vaccine in pediatric oncology patients. Pediatr. Blood Cancer 49(7), 918-923 (2007).
51. Lin PL, Michaels MG, Green M et al. Safety and immunogenicity of the American Academy of Pediatrics - recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics 116(1), 160-167 (2005).
52. Birx DL, Rhoads JL, Wright JC, Burke DS, Redfield RR. Immunologic parameters in early-stage HIV-seropositive subjects associated with vaccine responsiveness. J. Acquir. Immune Defic. Syndr. 4(2), 188-196 (1991).
53. Cetron MS, Marfin AA, Julian KG et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm. Rep. 51(RR-17), 1-11 (2002).
54. Fishman JA. Smallpox and live-virus vaccination in transplant recipients. Am. J. Transplant. 3(7), 786-793 (2003).
55. Ljungman P. Vaccination of transplant recipients. In: Transplant Infections. Bowden RA, Ljungman P, Paya CV (Eds). Lippincott Williams & Wilkins, PA, USA 611-624 (2003).
56. Mileno M. Preparation of immunocompromised travelers. In: Travel Medicine (1st edition). Keystone JS, Freedman DP, Nothdurft HD, Connor BA (Eds). Mosby, Edinburgh, UK 249-255 (2004).
57. Gowda R, Cartwright K, Bremner JA, Green ST. Yellow fever vaccine: a successful vaccination of an immunocompromised patient. Eur. J. Haematol. 72(4), 299-301 (2004).
58. Receveur MC, Thiebaut R, Vedy S, Malvy D, Mercie P, Bras ML. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin. Infect. Dis. 31(3), E7-E8 (2000).
59. Tattevin P, Depatureaux AG, Chapplain JM et al. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS 18(5), 825-827 (2004).
60. Ho YL, Enohata T, Lopes MH, De Sousa Dos Santos S. Vaccination in Brazilian HIV-infected adults: a cross-sectional study. AIDS Patient Care STDS 22(1), 65-70 (2007).
61. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J. Med. Assoc. Thai. 85(1), 131-134 (2002).
62. Gibbons RV, Rupprecht CE. Postexposure rabies prophylaxis in immunosuppressed patients. JAMA 285(12), 1574-1575 (2001).
63. + T lymphocyte counts. Clin. Infect. Dis. 33(10), E122-E124 (2001).
64. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 42(RR-1), 1-15 (1993).
65. Rojanasuphot S, Shaffer N, Chotpitayasunondh T et al. Response to JE vaccine among HIV-infected children, Bangkok, Thailand. Southeast Asian J. Trop. Med. Public Health 29(3), 443-450 (1998).
66. Puthanakit T, Aurpibul L, Yoksan S, Sirisanthana T, Sirisanthana V. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 25(49), 8257-8261 (2007).
67. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 56(RR-4), 1-40 (2007).
68. Panackal AA, Hajjeh RA, Cetron MS, Warnock DW. Fungal infections among returning travelers. Clin. Infect. Dis. 35(9), 1088-1095 (2002).
69. Hackett PH, Roach RC. High-altitude illness. N. Engl. J. Med. 345(2), 107-114 (2001).
70. Adult immunization schedule, United States October 2007-September 2008 www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm (Accessed 27 April 2008)
71. WHO: initiative for vaccine research: typhoid fever www.who.int/ vaccine_research/diseases/diarrhoeal/en/index7.html (Accessed 27 April 2008)
72. Search for Yellow Fever Vaccination Clinics www2.ncid.cdc.gov/travel/ yellowfever (Accessed 27 April 2008)